Abstract |
There are several reports describing acute liver decompensation in chronic carriers of HBsAg after withdrawal of chemotherapy or immunosuppressive therapy; recently the same was also reported for chronic HCV- RNA carriers. We retrospectively evaluated hepatic toxicity in eleven patients (6 carriers of HCV- RNA and 5 of HBsAg) autotransplanted at our Institution between March '92 and June '98. Male/female ratio was 7/4, median age 41 years (26-56). Nine patients (4 HBsAg) were affected by non-Hodgkin's lymphoma, 1 (HCV- RNA) by chronic myelogenous leukaemia and 1 ( HBsAg) by breast cancer. In the immediate post-transplant period in only 1 patient ( HBsAg carrier and affected by breast cancer) was hepatitis documented (at about 1 month from transplant) with an elevation of transaminase levels (x20-40 n.v.). Neither other complications, nor toxic deaths were observed. During the post-transplant follow-up (median 31 months, range 9-83) no hepatic abnormalities were observed. All patients are alive at 56 months (20-122) from diagnosis. Currently 10/11 patients are in complete remission, while 1 patient, affected by follicular centre lymphoma, is alive with disease 52 months from autologous stem cell transplantation. Our study shows that both conventional therapy and high-dose chemotherapy can be performed safely in chronic hepatitis B and C virus carriers.
|
Authors | A Sperotto, F Silvestri, R Fanin, D Damiani, A Geromin, M Cerno, R Stocchi, F Patriarca, M Baccarani |
Journal | Leukemia & lymphoma
(Leuk Lymphoma)
Vol. 36
Issue 3-4
Pg. 323-30
(Jan 2000)
ISSN: 1042-8194 [Print] United States |
PMID | 10674904
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents, Alkylating
- Busulfan
- Melphalan
|
Topics |
- Adult
- Antineoplastic Agents, Alkylating
(therapeutic use)
- Busulfan
(therapeutic use)
- Carrier State
- Feasibility Studies
- Female
- Follow-Up Studies
- Hematopoietic Stem Cell Transplantation
- Hepatitis B, Chronic
(complications)
- Hepatitis C, Chronic
(complications)
- Humans
- Liver
(drug effects, metabolism)
- Lymphoma
(complications, drug therapy, therapy, virology)
- Male
- Melphalan
(therapeutic use)
- Middle Aged
- Transplantation Conditioning
- Transplantation, Autologous
|